Inefficient nuclear transport of plasmid DNA continues to pCMV/T7-T7pol in an autoregulatory mechanism. be a problem in nonviral vector-mediated gene transfer.
Introduction
Many gene transfer vectors are efficient in delivering DNA into the cytoplasm of cells; however, the ultimate expression of the DNA is still hindered by inefficient transport of DNA into the nucleus where the transcription machinery resides. 1, 2 Attempts to increase the efficiency of nuclear transport of DNA, such as the use of a nuclear localization signal peptide, 3 have achieved only limited success. To overcome this obstacle, a cytoplasmic expression system was developed by utilizing a reporter gene driven by a bacteriophage T7 promoter. 4 Expression of this gene is dependent on co-delivery of T7 RNA polymerase which remains largely in the cytoplasm due to the lack of a nuclear localization signal. 5, 6 T7 RNA polymerase can drive expression of a reporter gene (pT7-CAT) in the cytoplasm; however, CAT expression decreases rapidly. It was hypothesized that this transient expression could be due to rapid degradation or inactivation of the T7 RNA polymerase enzyme.
Several T7 RNA polymerase autogenes, [7] [8] [9] [10] such as pT7 AUTO 2C − ( Figure 1 ) 11 have been developed to continuously produce high levels of T7 RNA polymerase in the cytoplasm. Co-delivery of pT7 AUTO 2C
− with purified T7 RNA polymerase enzyme induced higher, more sustained levels of reporter gene expression than that seen with exogenous T7 RNA polymerase enzyme alone. There are, however, several problems associated with the use of pT7 AUTO 2C
− and other autogenes. The process of amplification and purification of these plasmids from bacteria require difficult and time-consuming procedures. [9] [10] [11] [12] These autogenes also require co-delivery of purified T7 RNA polymerase enzyme for initiation of expression which is not only expensive, but potentially immunogenic. Finally, in the presence of the T7 AUTO 2C − autogene, CAT expression was only sustained for a few days with some cytotoxic effects.
We have developed a new T7 RNA polymerase autogene, pCMV/T7-T7pol, consisting of the T7 RNA polymerase gene driven by a CMV and T7 promoter ( Figure  1 ). pCMV/T7-T7pol has several advantages over previously used autogenes such as pT7 AUTO 2C − in that it avoids the problems mentioned previously while producing higher, more sustained levels of gene expression with no apparent cytotoxicity.
Results
pCMV/T7-T7pol produces higher T7 RNA polymerase and CAT expression than pT7 AUTO 2C − pCMV/T7-T7pol is an autogene which is driven by a dual promoter system consisting of a CMV promoter and a T7 promoter (Figure 1 ). This makes pCMV/T7-T7pol different from previously used autogenes such as pT7 AUTO 2C − since they are driven by the T7 promoter only (Figure 1 ). pT7 AUTO 2C
− has been previously shown to increase the duration of reporter gene expression as compared with exogenous T7 RNA polymerase protein alone; however, reporter gene expression remained elevated for only 3-4 days after transfection. 11 We investigated whether pCMV/T7-T7pol has the ability to induce higher levels of CAT expression over longer periods of time when compared with pT7 AUTO 2C − (Figure 2a ). Total CAT activity increased steadily up to 5 days after transfection with pCMV/T7-T7pol with no further increase to day 7. In comparison, the activity seen with pT7 AUTO 2C
− was not only much lower than that seen with pCMV/T7-T7pol, but it was only detectable for 4 days after transfection. pT7 AUTO 2C
− was completely dependent on co-delivery of exogenous T7 RNA polymerase since transfections with pT7 AUTO 2C − alone resulted in no detectable activity (data not shown). pCMV/T7-T7pol, however, did not require exogenous T7 RNA polymerase.
It is possible that pCMV/T7-T7pol could produce higher levels of T7 RNA polymerase over the 7-day period as compared with pT7 AUTO 2C − . After Western blot analysis using an anti-T7 RNA polymerase primary antibody, it became apparent that pCMV/T7-T7pol did induce high levels of T7 RNA polymerase over the 7-day period (Figure 2b ). The levels of T7 RNA polymerase in T7 AUTO 2C − transfected cells were too low to be detected. Figure 2b also shows the total calculated amount of T7 RNA polymerase in each cell lysate. The T7 RNA polymerase produced by pCMV/T7-T7pol increased up to day 3 and then steadily decreased to 65% of its peak level between days 5-7 ( Figure 2b ). Therefore, pCMV/T7-T7pol produces more T7 RNA polymerase than pT7 AUTO 2C
− causing a further increase in reporter gene transcription.
Endogenously produced T7 RNA polymerase and CAT protein levels remain stable up to 24 h after cycloheximide treatment Though T7 RNA polymerase produced by pCMV/T7-T7pol was greatly decreased by day 7, the CAT activity in the transfected cells continued to remain elevated ( Figure 2a) . It is possible that this T7 RNA polymerase expression vector produces high levels of T7 RNA polymerase up to 3-5 days after transfection before it is degraded or inactivated. This would induce increasing levels of CAT expression. After day 5, CAT activity would then plateau due to degradation of the T7 RNA polymerase protein. Though it has been hypothesized that T7 RNA polymerase could be rapidly degraded or inactivated in the cytoplasm, 4 the stability of T7 RNA polymerase has never been reported.
293 Cells were transfected with pCMV/T7-T7pol and then lysed up to 3 days after transfection. Cycloheximide, a potent protein synthesis inhibitor, was then added to the remaining cells 3 days after transfection to prevent any new synthesis of T7 RNA polymerase. As seen in Figure 3a , there was no change in the levels of T7 RNA polymerase protein during the 24 h that cycloheximide was present. This suggests a half-life for T7 RNA polymerase greater than 24 h which is longer than what was predicted previously. By looking at the CAT activity produced in the same cells after cycloheximide addition, it is evident that CAT protein is also quite stable indicating a half-life longer that 24 h (Figure 3b ).
pT7-CAT and pCMV/T7-T7pol (cytoplasmic expression) induced higher levels of CAT activity when compared with pCMV-CAT (nuclear expression) This cytoplasmic expression system was also compared with the nuclear expression system pCMV-CAT. pT7-CAT was co-delivered with increasing levels of pCMV/T7-T7pol (0.3-2 g) and the resulting CAT activities were compared with cells transfected with pCMV-CAT ( Figure 4 ). CAT activities produced by co-transfections of pT7-CAT and pCMV/T7-T7pol were higher than those seen in pCMV-CAT transfections. Activity increased in a dose-dependent manner with 2 g of pCMV/T7-T7pol producing four-fold higher activities than that seen with the pCMV-CAT nuclear system. Similar results were seen when a carrier DNA plasmid (pCMV-LacZ) was co-transfected in each condition to make the total DNA/liposome dose equal in all treatment groups (data not shown). When high concentrations of pCMV/T7-T7pol were used for time course studies, CAT activity (which exceeded that of pCMV-CAT) peaked 24 h after transfection and then decreased steadily to day 7 (data not shown).
The T7 promoter in pCMV/T7-T7pol produced higher levels of T7 RNA polymerase mRNA than the nuclear CMV promoter It is questionable whether the T7 promoter in pCMV/T7-T7pol plays a major role in T7 RNA polymerase protein production due to the lack of an internal ribosome entry site (IRES). This sequence is essential for efficient translation of uncapped mRNA transcribed by the T7 bacteriophage promoter. 6, 13 Transcription via the T7 promoter in pCMV/T7-T7pol could produce large amounts of T7 RNA polymerase mRNA; however, the majority of the transcripts would remain untranslated resulting in inefficient T7 RNA polymerase protein production. To test this possibility, the T7 promoter of pCMV/T7-T7pol was deleted by overlap PCR resulting in pCMV/⌬T7-T7pol. This new vector was transfected with pT7-CAT to 293 cells and compared in a parallel transfection with the original pCMV/T7-T7pol expression vector (Figure 5a ). pCMV/⌬T7-T7pol produced CAT expression levels which were slightly lower than CAT activity detected in pCMV/T7-T7pol transfected cells, particularly when the highest concentrations (0.7-1.0 g) of T7 RNA polymerase expression vector were utilized.
The level of mRNA production from both the CMV and the T7 promoters of pCMV/T7-T7pol were also tested using primer extension (Figure 5b) . A 20-bp 32 P- labeled reverse primer which binds to a region within the T7 RNA polymerase RNA (116 nucleotides from the ATG start site) was used for reverse transcription of the mRNA transcripts from pCMV/T7-T7pol and pCMV/⌬T7-T7pol. Transcription from the CMV promoter begins approximately 30 nucleotides before the T7 promoter (20 nucleotides) resulting in mRNA products which are 50 nucleotides longer in length than T7 RNA polymerase mRNA transcribed from the T7 promoter. The autoradiograph revealed two bands of approximately 170 (CMV promoter) and 120 (T7 promoter) nucleotides in length in cells transfected with pCMV/T7-T7pol (lane a). The intensity of the 120 nucleotide band (T7 promoter transcribed mRNA) was at least 50-fold higher than that of the 170 nucleotide band (CMV promoter transcribed mRNA). T7 RNA polymerase mRNA isolated from cells transfected with pCMV/⌬T7-T7pol produced a band of approximately 150 nucleotides because of the T7 promoter deletion (lane b). The intensity of this band was about two-fold higher than the 170 nucleotide band in lane a. These results provide strong evidence that pCMV/T7-T7pol is indeed working as an autogene. T7 RNA polymerase continuously cycles back to the T7 promoter to transcribe larger amounts of T7 RNA polymerase mRNA than that transcribed by the nuclear CMV promoter.
Discussion
We have created a novel T7 RNA polymerase autogene, pCMV/T7-T7pol, that is superior to those previously used in cytoplasmic expression systems. Several problems exist when using other autogenes such as pT7 AUTO 2C − . For instance, these autogenes are difficult to amplify and purify from bacteria. 11 It was hypothesized that the functional T7 promoter within the autogenes induced toxic levels of T7 RNA polymerase which killed the host bacteria. 9 Therefore, difficult and time-consuming procedures are required to inhibit the production of toxic levels of T7 RNA polymerase. 9, 11, 12 On the contrary, pCMV/T7-T7pol is easily amplified and purified from bacteria using standard methods. Ten micrograms of pCMV/T7-T7pol can be purified from a 1 liter culture of bacteria as compared with the 100 g of pT7 AUTO 2C − obtained per liter. It is possible that the CMV promoter in pCMV/T7-T7pol could induce conformational changes thereby causing steric hindrance that would interfere with T7 RNA polymerase binding to the T7 promoter in E. coli. When this plasmid is present in mammalian cells, additional factors could aid in a more open conformation, allowing T7 RNA polymerase binding to the T7 promoter for transcription.
Another downfall of the previously used autogenes is their dependence on co-delivery of purified T7 RNA polymerase protein to initiate transcription of the autogene at the T7 promoter. Co-delivery of exogenous T7 RNA polymerase, especially in vivo, can be very expensive and potentially immunogenic. pCMV/T7-T7pol does not require exogenous T7 RNA polymerase to initiate transcription. Once pCMV/T7-T7pol enters the cell via endocytosis, some of the DNA is released into the cytoplasm ( Figure 6 ). A portion of pCMV/T7-T7pol DNA will be transported to the nucleus where transcription will be initiated at the CMV promoter. This T7 RNA polymerase mRNA would then be transported into the cytoplasm for translation. This newly synthesized protein could then recognize the T7 promoter located on pCMV/T7-T7pol and begin transcription in the cytoplasm through an autoregulatory mechanism (ie autogene mechanism). Therefore, pCMV/T7-T7pol could continuously supply the cell with a source of T7 RNA polymerase to transcribe target genes containing a T7 promoter (eg pT7-CAT) in the cytoplasm. 
pCMV/T7-T7pol and pT7-CAT are delivered to cells via liposomes and the complex is endocytosed (1). The majority of the DNA released from the endosomes remains in the cytoplasm (2) while a small amount is transferred to the nucleus (3). The portion of pCMV/T7-T7pol that enters the nucleus is transcribed by RNA polymerase II to generate T7 RNA polymerase mRNA (4) that is translated in the cytoplasm (5). The T7 RNA polymerase produced then drives further T7 RNA polymerase expression in the cytoplasm by way of the T7 promoter on pCMV/T7-T7pol (6) (via an autogene mechanism) which would also drive expression of the CAT gene located on pT7-CAT (7). Therefore, this pCMV/T7-T7pol requires no addition of exogenous T7 RNA polymerase and takes advantage of the excess DNA remaining in the cytoplasm due to inefficient nuclear transport.
One of the greatest advantages of this new T7 RNA polymerase autogene is its ability to induce higher, more sustained levels of reporter gene expression (CAT activity) than that seen with autogenes such as T7 AUTO 2C − (Figure 2a) . When pCMV/T7-T7pol and pT7 AUTO 2C
− were compared in co-transfections with pT7-EGFP (enhanced green fluorescent protein gene driven by the T7 promoter), it was apparent that the percentage of cells transfected were the same; however, the degree of fluorescence was several times higher with pCMV/T7-T7pol indicating overall higher reporter gene expression (data not shown). This seems to be due to the fact that pCMV/T7-T7pol produced high amounts of T7 RNA polymerase protein in transfected cells which was then available to initiate high levels of reporter gene expression (Figure 2b ). The levels of T7 RNA polymerase produced by T7 AUTO 2C − were so low that they were not detectable by Western blot analysis (Figure 2b) . The high levels of CAT activity produced by pT7-CAT and pCMV/T7-T7pol transfections continued to increase up to 5 days (Figure 2a) . After day 5, total CAT activity remained constant up to day 7. This halt in reporter gene expression could be due to decreasing levels of T7 RNA polymerase. T7 RNA polymerase seems to be continuously synthesized up to 3-5 days after transfection as seen by calculating the total amount T7 RNA polymerase present in the transfected cell population (Figure 2b) . However, by day 7, over half of the T7 RNA polymerase is diminished. This could be due to a shutdown of T7 RNA polymerase expression between days 3 and 5, probably because of degradation or inactivation of the pCMV/T7-T7pol plasmid. In this way, no new T7 RNA polymerase would be synthesized and the protein would be degraded. Once T7 RNA polymerase is produced, it can then locate and transcribe CAT from the pT7-CAT plasmid. CAT expression continued to increase in the presence of increasing T7 RNA polymerase levels to day 5. No further increase in activity was seen after day 5 probably because pT7-CAT and/or T7 RNA polymerase protein was degraded. Figure 2b demonstrates a degradation of half of the synthesized T7 RNA polymerase protein between days 5 and 7. This suggests a half-life longer than 24 h which is longer than was previously thought. 4, 11 Transfections with T7 RNA polymerase alone induced transient CAT activity in cells which was hypothesized to be due to rapid degradation of the T7 RNA polymerase. 4 T7 RNA polymerase autogenes were created to solve the problem of rapid degradation by providing a high, continuous supply of T7 RNA polymerase protein. However, no data are available to show that T7 RNA polymerase is rapidly degraded in transfected cells. To investigate this issue, a potent protein synthesis inhibitor, cycloheximide, was added to cells 3 days after transfection followed by cell lysis at 6, 12, and 24 h after treatment. This would prevent synthesis of new T7 RNA polymerase so that degradation of previously produced T7 RNA polymerase could be studied over a 24 h period. As seen in Figure 3a , the level of T7 RNA polymerase remained the same up to 24 h after the protein synthesis block, indicating a halflife of T7 RNA polymerase which is greater than 24 h. This is in agreement with the results found in Figure 2b . As seen in Figure 3b , CAT protein also remained stable 24 h after cycloheximide addition. This would explain why there was no apparent decrease in total CAT activity from days 5 to 7 after transfection (Figure 2a) , since it is a result of a large decrease in synthesis but a slow degradation of CAT protein.
When the T7 promoter was deleted from pCMV/T7-T7pol, it became apparent that the T7 promoter made a relatively small contribution to the level of T7 RNA polymerase protein produced. This was indicated by a small decrease in CAT activity (Figure 5a ). This small contribution of the T7 promoter was to be expected since pCMV/T7-T7pol does not contain an IRES sequence necessary for efficient translation of uncapped T7 RNA polymerase mRNA. This results in a large amount of untranslated mRNA left in the cytoplasm. By utilizing primer extension techniques, the amount of mRNA produced from each promoter (CMV, T7) in pCMV/T7-T7pol was assessed (Figure 5b, lane a) . The 120 nucleotide band corresponding to T7 promoter transcribed mRNA was more than 50-fold higher in intensity than the 170 nucleotide band corresponding to CMV promoter transcribed mRNA. When the same procedures were performed on cells transfected with pCMV/⌬T7-T7pol, the band intensity was around two-fold higher than that of the CMV promoter transcribed mRNA from pCMV/T7-T7pol. This is probably because deletion of the T7 pro-moter will delete any steric hindrance so that the CMV promoter is no longer inhibited. These results indicate that pCMV/T7-T7pol is functioning as an efficient T7 RNA polymerase autogene, ie the T7 promoter in the construct is responsible for the major portion of T7 RNA polymerase mRNA production. pCMV/T7-T7pol can produce over 50-fold higher levels of T7 RNA polymerase mRNA than a vector relying only on a CMV nuclear promoter. However, the abundant mRNA from the T7 promoter is mostly untranslated because the CAT activity driven by pCMV/⌬T7-T7pol was only slightly lower than that driven by pCMV/T7-T7pol. When the T7 RNA polymerase protein levels are analyzed by Western blot under the same transfection conditions, the intensity of the T7 RNA polymerase protein band is four to five times lower in pCMV/⌬T7-T7pol-transfected cells (data not shown). This indicates that the T7 promoter in pCMV/T7-T7pol is indeed functional and that some of the uncapped mRNA transcripts from the T7 promoter are being translated. Therefore, it would be advantageous to add an IRES sequence to pCMV/T7-T7pol to enhance translation of the remaining uncapped mRNA transcribed from the T7 promoter. This will increase T7 RNA polymerase protein levels to induce higher levels of transgene transcription. These experiments are in progress and will be published elsewhere.
pCMV/T7-T7pol takes advantage of the large amount of DNA that remains in the cytoplasm after transfection. Therefore, this system should be more efficient in expressing delivered genes than a nuclear expression system. These systems were compared by examining cells transfected with pCMV-CAT or with pT7-CAT co-delivered with increasing concentrations of pCMV/T7-T7pol (Figure 4 ). CAT activity with the cytoplasmic expression system exceeded that of nuclear expression when sufficient amounts of pCMV/T7-T7pol (0.7-2.0 g) were used. When high concentrations of pCMV/T7-T7pol are used (0.7-2.0 g), high CAT activity could be detected as early as day 1 followed by a continuous decrease to day 7 (data not shown). This is a very different trend from that seen at lower pCMV/T7-T7pol concentrations (Figure 2a, 0.3 g) probably because higher concentrations produce more T7 RNA polymerase driving reporter gene expression in the cytoplasm at a much earlier time-point. It should be noted that current liposomal vectors are optimized for the nuclear expression system. 14 Even though these liposome formulations are effective for cytoplasmic expression systems, their efficiency may be far from optimal. Further efforts towards developing delivery formulations more suitable for cytoplasmic expression may result in further increases in overall gene expression.
In conclusion, we have developed a new T7 RNA polymerase expression vector, pCMV/T7-T7pol, that is superior to autogenes used previously in the cytoplasmic expression system. It induces high, sustained levels of CAT activity which are higher than that seen with previous autogenes such as T7 AUTO 2C
− or with nuclear expression systems such as pCMV-CAT. This is due to the high levels of T7 RNA polymerase produced by pCMV/T7-T7pol. This new autogene is yet to be tested in a gene therapy application; however, it could make an important contribution to the field of gene therapy mediated by nonviral vectors.
Materials and methods
DC-chol:DOPE liposomes 3␤[N-(NЈ,NЈ-dimethylaminoethane)-carbamoyl] cholesterol (DC-chol) was synthesized as previously described.
14 Microfluidization of a hydrated mixture of DC-chol and dioleoylphosphatidylethanolamine (DOPE) in a 3:2 molar ratio was followed by filter sterilization to form unilamellar, small liposomes (approximately 150 nm in diameter). 15 
Plasmids
Plasmid pT7-CAT which is the same as pT7-EMC-CAT, a plasmid containing the CAT reporter gene driven by the bacteriophage T7 promoter, 13 was a kind gift provided by Dr B Moss, National Institute of Health. pCMV-CAT used for nuclear expression of the CAT gene driven by the human cytomegalovirus immediate-early promoter (CMV) was constructed in our laboratory by Hassan Farhood.
16 pT7 AUTO 2C − (Figure 1b) , an autogene composed of the T7 RNA polymerase gene and its corresponding promoter, was maintained and purified as previously described.
11 pCMV/T7-T7pol was constructed as an expression plasmid for the T7 RNA polymerase gene driven by its cognate T7 promoter and the human CMV promoter. A HindIII/BamHI fragment from pAR3126 5 containing the cDNA of T7 RNA polymerase was inserted into the corresponding sites of the pcDNA3 plasmid vector (Invitrogen, San Diego, CA, USA) to generate pCMV/T7-T7pol (Figure 1a) . The T7 promoter of pCMV/T7-T7pol was deleted by overlap PCR methodology to produce pCMV/⌬T7-T7pol. These vectors were amplified in E. coli DH5␣ cells and purified by CsCl gradient centrifugation methods. 17 
Cell lines
Human embryonic kidney 293 cells transformed with adenoviral E1a/b were cultured in DMEM medium containing 10% fetal bovine serum, penicillin (200 U/ml) and streptomycin (100 g/ml). All cells were grown to 70-80% confluency in 24-well plates before transfection.
Transfections pT7-CAT (1 g per well) diluted in serum-free DMEM medium was mixed with 150 U of T7 RNA polymerase (New England Biolabs, Beverly, MA, USA), 0.3-2.0 g of either pCMV/T7-T7pol or pT7 AUTO 2C
− or a combination of enzyme and polymerase expression vector before complexing with DC-chol:DOPE liposomes (1 g DNA/10 nmol lipid). Comparison transfections between pCMV/T7-T7pol and pCMV/T7⌬-T7pol were performed in a similar manner with concentrations ranging between 0-2.0 g of either plasmid. These mixtures were used to transfect cells for 4 h at 37°C after which transfection medium was replaced with growth medium. Cells were incubated for an additional 2 days at 37°C following transfection before cell lysis and CAT assay. For pCMV-CAT, 1 g of DNA was complexed with DC-chol:DOPE liposomes (1 g DNA/10 nmol lipid) for transfection. For time-course studies, cells were split 1:1 at day 4 and were lysed daily up to 7 days after transfection for CAT assay. Cycloheximide (Sigma, St Louis, MO, USA) was used as a protein synthesis inhibitor to observe the degradation rates of T7 RNA polymerase and CAT protein. In these experiments, cells were lysed on days 2 and 3 after transfection with pCMV/T7-T7pol (0.3 g) and pT7-CAT (1 g) via DC-chol:DOPE liposomes (10 nmol lipid per g DNA). On day 3 after transfection, the remaining transfected cells were treated with 25 g per well cycloheximide in DMEM medium and lysed at 0, 6, 12 and 24 h after drug treatment. Using radiolabeled 35 Smethionine incorporation techniques, a 95% inhibition of protein synthesis was determined at 25 g per well of cycloheximide. Cytotoxicity due to cycloheximide addition was only apparent when drug treatment exceeded 24 h. Toxicity was determined by comparing the total protein remaining in each well following transfection with the total protein remaining in untreated wells. Total protein was measured by Coomassie Plus Protein Assay Reagent (Pierce, Rockford, IL, USA).
Western blots
The goat anti-T7 RNA polymerase polyclonal antibody was a kind gift from Dr Paul Fisher at the Department of Pharmacological Sciences, State University of New York at Stony Brook. Four micrograms of total protein from transfected cell lysates was electrophoresed on a 7.5% SDS-PAGE and transferred to a 0.2 m nitrocellulose membrane (Schleicher & Schuell, Keene, NH, USA). Equal protein loading and efficiency of transfer was quantified by a Poncheau S stain following Western blot transfer. The membrane was first blocked in PBS buffer containing 0.2% Tween-20 and 5% dry milk overnight at 4°C. The membrane was then incubated with goat anti-T7 RNA polymerase polyclonal antibody (1:2500) followed by incubation with rabbit-anti-goat horseradish peroxidase labeled secondary antibody (1:5000, American Qualex, San Clemente, CA, USA). Cycloheximide experiment blots were hybridized with a secondary antibody dilution of 1:10 000 to reduce elevated background levels. The specified band was visualized by an ECL kit from Amersham Life Sciences, Buckinghamshire, UK. One unit of purified T7 RNA polymerase was used as a positive control while untreated 293 cell lysates were used as negative controls. The total levels of T7 RNA polymerase protein in the Western blot analysis (Figure 2b ) were calculated by normalizing for total protein. The intensity of each band was measured by densitometry giving the T7 RNA polymerase intensity value/4 g total protein analyzed. Each value was multiplied by the total protein found in the entire lysate and divided by 1000 to give T7 RNA polymerase intensity levels in relative units.
CAT assay
Following transfection, cells were washed once with PBS and lysed with 200 l of lysis buffer consisting of 0.1% Triton X-100 (Sigma) in 200 mm Tris-HCl (pH 7.8). CAT assays were performed according to the methods described, 8 with a few modifications. One mm chloramphenicol (Sigma), 0.1 mm acetyl CoA (Sigma), and 0.1 Ci 3 H-acetyl CoA (ICN Biomedicals, Costa Mesa, CA, USA) were used for the assay mixture. The product of the reaction, acetylated chloramphenicol, was extracted from the aqueous phase with 1 ml of toluene. One half of the organic phase was then mixed with 3 ml of Beta-Max (ICN Biomedicals) and counted for radioactivity. One unit was defined as the amount of enzyme converting 1 nmol of acetyl groups to chloramphenicol per minute at the above reaction conditions.
Primer extension
A 20 nucleotide reverse primer (120 ng), which hybridizes to RNA products extracted from cells transfected with either pCMV/T7-T7pol or pCMV/⌬T7-T7pol, was end-labeled with ␥-32 P-ATP by the addition of T4 polynucleotide kinase (New England Biolabs) at 37°C for 30 min. Total RNA was isolated by Ultraspec RNA (Biotecx Laboratories, Houston, TX, USA) from nontransfected 293 cells or cells transfected with 1 g each of pCMV/T7-T7pol ϩ pT7-CAT or 1 g each of pCMV/⌬T7-T7pol + pT7-CAT. 45-50 g of RNA was added to 3 l of labeled primer in 45 l of hybridization buffer consisting of 0.4 m NaCl, 50 mm PIPES (pH 6.4) and 1 mm EDTA. The reaction mixtures were incubated at 85°C for 10 min and then at 40°C for at least 4 h. The hybridized products were precipitated and added to a primer extension reaction buffer consisting of 5 × reverse transcription buffer (Promega, Madison, WI, USA), 10 mm dNTP mix (Promega) 40 U RNase inhibitor (Boehringer Mannheim, Indianapolis, IN, USA), 3.5 g actinomycin D (Sigma), and 20 U AMV reverse transcriptase enzyme (Promega) for 1-2 h at 45°C. 0.5 g of RNase (Boehringer Mannheim) was then added for 20 min at 37°C. The DNA products were precipitated and dissolved in 8 l of TE buffer and mixed with 12 l of loading buffer (formamide, 500 mm EDTA, 1% bromophenol blue). The products were resolved on a 10% urea PAGE gel and exposed to radiographic film overnight.
